Richard Edward Armer

This inventor holds 11 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 3 EPO patents. Top assignees: Oxagen Limited, Atopix Therapeutics Limited, Tel Aviv University. Active years: 2010-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard Edward Armer. Retrieved from https://idiyas.com/inventor/richard-edward-armer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 1)

% Patents Active = 45.5

CIPO Patents = 1

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.8

ph-index = 6

Forward Citations = 133(Granted Patents)

Location History:

Oxon, GB (2010 - 2015)
Cambridge, GB (2011 - 2016)
Cambridgeshire, GB (2017)

Company Filing History:

Atopix Therapeutics Limited

Years Active: 2010-2017

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9675567 - Potassium ion channel modulators and uses thereof (2017-06-13),

2. 9464052 - Potassium ion channel modulators and uses thereof (2016-10-11),

3. 8980927 - Compounds having CRTH2 antagonist activity (2015-03-17),

4. 8563536 - Compounds having CRTH2 antagonist activity (2013-10-22),

5. 8536158 - Compounds having CRTH2 antagonist activity (2013-09-17),

6. 8268878 - Compounds having CRTH2 antagonist activity (2012-09-18),

7. 8168673 - Compounds having CRTH2 antagonist activity (2012-05-01),

8. 8044088 - 1-acetic acid-indole derivatives with PGD2 antagonist activity (2011-10-25),

9. 7999119 - Compounds having CRTH2 antagonist activity (2011-08-16),

10. 7919512 - Compounds having CRTH2 antagonist activity (2011-04-05),

11. 7750027 - Compounds having CRTH2 antagonist activity (2010-07-06),

Title: Richard Edward Armer: Innovator in Potassium Ion Channel Modulation

Introduction

Richard Edward Armer is a notable inventor based in Oxon, GB. He has made significant contributions to the field of pharmacology, particularly in the development of potassium ion channel modulators. With a total of 11 patents to his name, Armer's work has the potential to impact various medical conditions.

Latest Patents

Among his latest patents is a groundbreaking invention related to potassium ion channel modulators and their uses. The compounds of formula (I) and their pharmacologically acceptable salts and pro-drugs are designed to treat and prevent conditions such as pain and lower urinary tract disorders. This innovative approach highlights the therapeutic potential of potassium ion channel modulation in modern medicine.

Career Highlights

Throughout his career, Richard Edward Armer has worked with several prominent companies, including Oxagen Limited and Atopix Therapeutics Limited. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Armer has collaborated with notable individuals in the field, including Graham Michael Wynne and Julia Vile. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Richard Edward Armer's contributions to the field of potassium ion channel modulation demonstrate his commitment to advancing medical science. His innovative patents and collaborations reflect his significant impact on the industry.

Profile summary based on public USPTO records.